Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
Design Therapeutics, Inc. (DSGN)
Company Research
Source: GlobeNewswire
CARLSBAD, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat at the 2024 RBC Capital Markets Healthcare Conference on Wednesday, May 15, 2024, at 11:30 a.m. ET in New York. A live webcast of the fireside chat will be available here and in the investors section of the company’s website at www.designtx.com. The webcast will be archived for 30 days following the presentation. About Design TherapeuticsDesign Therapeutics is a biotechnology company developing a new class of therapies based on its platform of GeneTAC™ gene targeted chimera small molecules. The company’s GeneTAC™ molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its lead GeneTAC™ small molecule, DT-216, in development for pa
Show less
Read more
Impact Snapshot
Event Time:
DSGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DSGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DSGN alerts
High impacting Design Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
DSGN
News
- Prefilled Syringes Market to Hit $22.8 Billion by 2029, Driven by Innovation and Demand Surge [Yahoo! Finance]Yahoo! Finance
- Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones [Yahoo! Finance]Yahoo! Finance
- Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program MilestonesGlobeNewswire
- Design Therapeutics, Inc. (NASDAQ: DSGN) was upgraded by analysts at Piper Sandler from a "neutral" rating to an "overweight" rating. They now have a $12.00 price target on the stock, up previously from $6.00.MarketBeat
DSGN
Earnings
- 3/19/24 - Beat
DSGN
Sec Filings
- 6/17/24 - Form 4
- 6/17/24 - Form 4
- 6/17/24 - Form 4
- DSGN's page on the SEC website